Literature DB >> 15483086

beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.

Ele Ferrannini1, Amalia Gastaldelli, Yoshinori Miyazaki, Masafumi Matsuda, Andrea Mari, Ralph A DeFronzo.   

Abstract

The nature of the progressive beta-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI] </= 25 kg/m(2)), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of beta-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, beta-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.1-7.7 mmol/liter), beta-cell glucose sensitivity declined by 50-70% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective beta-cell potentiation and rate sensitivity also emerged (P </= 0.05). In the whole data set, insulin sensitivity and the dynamic parameters of beta-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) beta-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of beta-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15483086     DOI: 10.1210/jc.2004-1133

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  172 in total

1.  A spectrum of dynamic insulin sensitivity test protocols.

Authors:  Paul D Docherty; J Geoffrey Chase; Lisa Te Morenga; Thomas F Lotz; Juliet E Berkeley; Geoffrey M Shaw; Kirsten A McAuley; Jim I Mann
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

2.  Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  S E Inzucchi; R M Bergenstal; J B Buse; M Diamant; E Ferrannini; M Nauck; A L Peters; A Tsapas; R Wender; D R Matthews
Journal:  Diabetologia       Date:  2012-04-20       Impact factor: 10.122

3.  Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids.

Authors:  Ximena Lopez; Aaron Cypess; Raquel Manning; Sheila O'Shea; Rohit N Kulkarni; Allison B Goldfine
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 4.  Treatment of prediabetes.

Authors:  Mustafa Kanat; Ralph A DeFronzo; Muhammad A Abdul-Ghani
Journal:  World J Diabetes       Date:  2015-09-25

5.  Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Authors:  D H Jensen; K Aaboe; J E Henriksen; A Vølund; J J Holst; S Madsbad; T Krarup
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

6.  Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes.

Authors:  T H Schindler; A D Facta; J O Prior; J Cadenas; W A Hsueh; M J Quinones; H R Schelbert
Journal:  Heart       Date:  2006-08-29       Impact factor: 5.994

Review 7.  The pancreatic β-cell transcriptome and integrated-omics.

Authors:  David M Blodgett; Anthony J Cura; David M Harlan
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-04       Impact factor: 3.243

Review 8.  Emerging treatments for post-transplantation diabetes mellitus.

Authors:  Trond Jenssen; Anders Hartmann
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

Review 9.  Anti-diabetic medications: How to make a choice?

Authors:  Amir Babiker; Mohammed Al Dubayee
Journal:  Sudan J Paediatr       Date:  2017

10.  Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.

Authors:  R A DeFronzo; M A Banerji; G A Bray; T A Buchanan; S Clement; R R Henry; A E Kitabchi; S Mudaliar; N Musi; R Ratner; P Reaven; D C Schwenke; F D Stentz; D Tripathy
Journal:  Diabetologia       Date:  2009-12-10       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.